• JM-010 is developed based on Contera Pharma’s new approach to identify and develop new treatment for patients suffering from serious disorders.

  • JM-010 is developed based on a poly-pharmacological approach to treat or prevent dyskinesia in Parkinson's disease. This will provide efficacy reducing involuntary movement without adverse effects. JM-010 has shown very convincing efficacy in preclinical and in Phase IIa cPoC. Based in the data JM-010 should provide a safe and efficacious treatment of dyskinesia in Parkinson's disease.

  • JM-010 is covered by several very strong patents to provide exclusivity until 2032 or later.